RT Journal Article
SR Electronic
T1 SARS-CoV-2 molecular testing and whole genome sequencing following RNA recovery from used BinaxNOW COVID-19 Antigen Self Tests
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.09.23284337
DO 10.1101/2023.01.09.23284337
A1 Nguyen, Phuong-Vi
A1 Carmola, Ludy Registre
A1 Wang, Ethan
A1 Bassit, Leda
A1 Rao, Anuradha
A1 Greenleaf, Morgan
A1 Sullivan, Julie A.
A1 Martin, Greg S.
A1 Lam, Wilbur A.
A1 Waggoner, Jesse J.
A1 Piantadosi, Anne
YR 2023
UL http://medrxiv.org/content/early/2023/01/09/2023.01.09.23284337.abstract
AB Widespread use of over-the-counter rapid diagnostic tests for SARS-CoV-2 has led to a decrease in availability of clinical samples for viral genomic surveillance. As an alternative sample source, we evaluated RNA isolated from BinaxNOW swabs stored at ambient temperature for SARS-CoV-2 rRT-PCR and full viral genome sequencing. 81 of 103 samples (78.6%) yielded detectable RNA, and 46 of 57 samples (80.7 %) yielded complete genome sequences. Our results illustrate that SARS-CoV-2 RNA extracted from used Binax test swabs provides an important opportunity for improving SARS-CoV-2 genomic surveillance, evaluating transmission clusters, and monitoring within-patient evolution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health under award U54 EB027690 and the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Emory Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences newly generated in this study were deposited in NCBI under BioProject PRJNA634356 and GISAID under accession numbers EPI_ISL_15938303-331. Sequences downloaded from GISAID are available at doi: 10.55876/gis8.221128zq.